Guidance, NICE advice and quality standards in development

Showing 171 to 180 of 383

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130]	Highly specialised technology	18 December 2024
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]	Technology appraisal guidance	TBC
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]	Technology appraisal guidance	TBC
Linzagolix for treating pain caused by endometriosis [ID6357]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]	Technology appraisal guidance	11 December 2024